This year, all 155 abstracts submitted for evaluation and accepted for presentation until end of September 2011 are included in this issue of the Journal of Cachexia, Sarcopenia and Muscle (JCSM). Abstracts accepted later will be printed in the first issue of 2012. Also, the number of abstracts has substantially increased since the initial conference (Fig. 1), and as you will see during the conference in Milan, an increased amount of space and time is given to poster discussions.
The first issue of JCSM has been published in September 2010. JCSM is published quarterly as a hard copy journal as well as on an open-access basis without page charges for authors. All submitted articles are undergoing peer review. In April 2011, after appearance of only its third issue, JCSM was accepted for indexing in PubMed®. We are proud to say that all issues of JCSM are included in PubMed® and can be downloaded free of charge from PubMed Central as well as from the journal’s dedicated websites at www.jcsm.info and www.jcsm.springer.de.
Since publication of the first issue of JCSM, three double-blind, randomized, placebo-controlled trials covering different aspects and therapeutic approaches to cachexia, have been included in the journal [1–3]. In addition, the rationale and design of two clinical studies (one a registry and the other a phase II clinical trial) have also been published in JCSM [4, 5]. We invite everyone to follow this example. Please help us to make JCSM the premier journal to read about dedicated treatment and prevention studies in the fields of cachexia and sarcopenia. According to Google Scholar, the total number of citations of all 12 articles published in 2010 alone sums up to 104 . Therefore, authors submitting to JCSM have a high likelihood of broad awareness of their results.
We were horrified when we learned about the tragic events in Fukushima and its surroundings that ultimately forced us to re-schedule our meeting. Our thoughts are with our Japanese colleagues and their families. We also sincerely hope that our next meeting in December 2013 can successfully take place in Kobe/Japan as originally planned for this year.
But now we are in Milan and we want to sincerely thank the local organizers, the society staff and all our supporters in academica and industry for having helped us to make this conference possible. We wish all participants of the 6th Cachexia Conference an interesting and stimulating meeting and hope to meet up during the sessions, the poster discussions, or at one of the evening events. Many of you will be contacted to submit original papers and/or reviews to our journal. Only through the exchange of ideas and scientific research results we can ultimately achieve what this is all about—improve the lives of our patients. Cachexia, sarcopenia, and muscle wasting are big medical needs, and you and your publications are a seminal building stone of future therapeutic successes. Please feel invited to submit your work to JCSM. We promise, we will give it our undivided attention and turn around your manuscripts fast.
|1.||Dalton JT, Barnette KG, Bohl CE,
Hancock ML, Rodriguez D, Dodson ST, et al. The selective androgen
receptor modulator GTx-024
(enobosarm) improves lean body mass and physical
function in healthy elderly men and postmenopausal women: results of a
placebo-controlled phase II trial. J Cachexia
Sarcopenia Muscle. 2011;3:153–61.
|2.||Chen F, Lam R, Shaywitz D, Hendrickson RC, Opiteck GJ, Wishengrad D, et al. Evaluation of early biomarkers of muscle anabolic
response to testosterone. J Cachexia Sarcopenia Muscle. 2011;1:45–56.
|3.||Rozentryt P, von Haehling S,
Lainscak M, Nowak JU, Kalantar-Zadeh K, Polonski L, et al. The effects
of a high-caloric protein-rich
oral nutritional supplement in patients with
chronic heart failure and cachexia on quality of life, body composition,
inflammation markers: a randomized, double-blind
pilot study. J Cachexia Sarcopenia Muscle. 2010;1:35–42.
|4.||von Haehling S, Lainscak M,
Doehner W, Ponikowski P, Rosano G, Jordan J, et al. Diabetes mellitus,
cachexia and obesity in
heart failure: rationale and design of the studies
investigating co-morbidities aggravating heart failure (SICA-HF). J
Sarcopenia Muscle. 2010;2:187–94.
|5.||Coats AJ, Srinivasan V, Surendran J, Chiramana H, Vangipuram SR, Bhatt NN, Jain M, Shah S, Ali IA, Fuang HG, Zailani M, Hassan M, Beadle J, Tilson J, Kirwan BA, Anker SD on behalf of the ACT-ONE Trial Investigators (2011) The ACT-ONE Trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design. J Cachexia Sarcopenia Muscle. doi:10.1007/s13539-011-0046-2 (in press)|
|6.||http://scholar.google.de (Accessed on 05 October, 2011)|
|7.||von Haehling S, Morley JE, Coats AJ, Anker SD. Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle. 2010;1:7–8.|